ISSN 1306-0015 | E-ISSN 1308-6278
Case Report
Effective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab
1 Division of Pediatric Allergy and Clinical Immunology, Department of Pediatric, Adnan Menderes University School of Medicine, Aydın, Turkey  
Turk Pediatri Ars ; : -
DOI: 10.5152/TurkPediatriArs.2018.4042
Key Words: Effective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab
Abstract

 

Omalizumab is a recombinant humanized monoclonal anti-IgE antibody. Until now, the efficiency of omalizumab in chronic spontaneous urticaria has been demonstrated in several studies.  However in the literature, data showing the efficiency of omalizumab in different phenotypes of H1-antihistamine-refractory chronic urticaria are limited. In this report, the success of treatment with omalizumab from the first dose is presented in three patients with chronic spontaneous urticaria, chronic autoimmune urticaria, and idiopathic angioedema, who were unresponsive to high-dose H1-antihistamine. The symptoms of all patients resolved with the first dose of omalizumab and no symptom recurrence developed during the follow-up period. In this case presentation, the effective treatment of different phenotypes of H1-antihistamine-refractory chronic urticaria is discussed with a review of the literature.

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2018 Turkish Pediatrics Association | Latest Update: 03.10.2018